US Stock MarketDetailed Quotes
RAPP Rapport Therapeutics
- 26.900
- +0.750+2.87%
Close Nov 7 16:00 ET
- 26.900
- 0.0000.00%
Post 16:20 ET
983.91MMarket Cap-15612P/E (TTM)
28.005High26.330Low105.86KVolume27.010Open26.150Pre Close2.88MTurnover1.15%Turnover RatioLossP/E (Static)36.58MShares29.74052wk High2.92P/B247.48MFloat Cap16.55052wk Low--Dividend TTM9.20MShs Float29.740Historical High--Div YieldTTM6.41%Amplitude16.550Historical Low27.210Avg Price1Lot Size
Rapport Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | |||||
| Cash flow from continuing operating activities | -147.80%-16.35M | -266.90%-17.62M | -27.18M | -6.6M | -4.8M |
| Net income from continuing operations | -182.65%-18.12M | -268.78%-22.67M | ---34.79M | ---6.41M | ---6.15M |
| Operating gains losses | --0 | 617.48%7.39M | --1.12M | --0 | --1.03M |
| Depreciation and amortization | 890.48%208K | 913.33%152K | --112K | --21K | --15K |
| Other non cash items | --159K | --156K | --267K | ---- | ---- |
| Change In working capital | 89.34%-123K | -648.10%-3.16M | --2.65M | ---1.15M | ---422K |
| -Change in prepaid assets | 173.95%900K | -241.58%-2.07M | ---3.2M | ---1.22M | ---606K |
| -Change in payables and accrued expense | -2,305.00%-882K | -367.70%-953K | --6.24M | --40K | --356K |
| -Change in other current assets | 4.35%24K | 115.70%27K | ---240K | --23K | ---172K |
| -Change in other current liabilities | ---165K | ---161K | ---144K | --0 | --0 |
| Cash from discontinued investing activities | |||||
| Operating cash flow | -147.80%-16.35M | -266.90%-17.62M | ---27.18M | ---6.6M | ---4.8M |
| Investing cash flow | |||||
| Cash flow from continuing investing activities | -124,439.53%-107.1M | -68,631.15%-41.93M | -78.86M | -86K | -61K |
| Net PPE purchase and sale | -1,024.42%-967K | -1,657.38%-1.07M | ---1.64M | ---86K | ---61K |
| Net investment purchase and sale | ---106.14M | ---40.85M | ---77.22M | --0 | --0 |
| Cash from discontinued investing activities | |||||
| Investing cash flow | -124,439.53%-107.1M | -68,631.15%-41.93M | ---78.86M | ---86K | ---61K |
| Financing cash flow | |||||
| Cash flow from continuing financing activities | 177,158.89%159.35M | 6.09%63.66M | 145.14M | -90K | 60.01M |
| Net issuance payments of debt | ---- | ---- | --0 | ---- | ---- |
| Net common stock issuance | 530,230.00%159.1M | --0 | --50K | --30K | --24K |
| Net preferred stock issuance | 63.75%-29K | 6.57%63.94M | --145.22M | ---80K | --60M |
| Net other financing activities | ---- | -1,472.22%-283K | ---134K | ---40K | ---18K |
| Cash from discontinued financing activities | |||||
| Financing cash flow | 177,158.89%159.35M | 6.09%63.66M | --145.14M | ---90K | --60.01M |
| Net cash flow | |||||
| Beginning cash position | -13.82%74.37M | 125.47%70.25M | --31.16M | --86.3M | --31.16M |
| Current changes in cash | 629.85%35.9M | -92.53%4.12M | --39.1M | ---6.78M | --55.14M |
| End cash Position | 38.65%110.27M | -13.82%74.37M | --70.25M | --79.53M | --86.3M |
| Free cash flow | -159.07%-17.32M | -284.35%-18.69M | ---28.82M | ---6.69M | ---4.86M |
| Currency Unit | USD | USD | USD | USD | USD |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
